Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DHX9 | ISIN: DK0061802139 | Ticker-Symbol: 4AJ0
Frankfurt
28.03.24
08:11 Uhr
16,470 Euro
+0,180
+1,10 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ALK-ABELLO A/S Chart 1 Jahr
5-Tage-Chart
ALK-ABELLO A/S 5-Tage-Chart
RealtimeGeldBriefZeit
16,45016,79011:03

Aktuelle News zur ALK-ABELLO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiALK Abello: Save the date for ALK's Capital Markets Day on 4 June 20241
14.03.ALK Abello: Annual General Meeting in ALK-Abelló A/S held on 14 March 20244
04.03.ALK Abello: Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff3
16.02.ALK Abello: Annual General Meeting in ALK-Abelló A/S on 14 March 20241
12.02.ALK Abello: Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff5
08.02.ALK Abello: Annual report 2023: ALK delivers 9% sales growth with profits up 50%27108 February 2024 ALK's (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company's 2023 annual report. Following a robust performance in Q4, full-year results were in line with the...
► Artikel lesen
07.02.ALK Abello: ALK and McMaster researchers discover new cell that remembers allergies189Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abelló A/S have made a ground-breaking discovery: a new cell that remembers allergies. The discovery gives scientists...
► Artikel lesen
05.02.ALK Abello: ALK's 2030 CO2 reduction targets have been approved by SBTi477ALK's near-term carbon reduction targets for scope 1, 2 and 3 have been validated and approved by the Science Based Targets initiative. Today, ALK announces that its near-term carbon reduction targets...
► Artikel lesen
31.01.ALK Abello: Release date of annual report 2023 for ALK and webcast3
25.01.ALK Abello: ALK's European registration application for house dust mite SLIT-tablet in young children accepted for review4
18.01.ALK Abello: ALK completes first part of phase 1 trial with peanut SLIT-tablet2
04.01.ALK Abello: ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy243- PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergyi,ii - The Danish, pharmaceutical company ALK (ALKB:DC...
► Artikel lesen
20.12.23ALK Abello: ALK - Financial calendar for the 2024 financial year4
12.12.23ALK Abello: ALK expands partnership with Torii in Japan276ALK (ALKB:DC / OMX: ALK B / AKBLF) and its Japanese partner Torii Pharmaceutical Co., Ltd. ('Torii') today announced that they have expanded their collaboration and entered into an additional license...
► Artikel lesen
15.11.23ALK Abello: Nine-month interim report (Q3) 2023267ALK delivers 8% revenue growth with operating profit up 128% in Q3 (unaudited) ALK saw growth in all sales regions in Q3, led by sales of tablets and SCIT. As expected, European tablet sales picked...
► Artikel lesen
11.10.23ALK Abello: Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK's tree tablet in children5
24.08.23ALK Abello: Six-month interim report (Q2) 2023230ALK delivers 11% revenue growth with operating profit up 120% in Q2 (unaudited) ALK's revenue grew by 11% in Q2 2023, driven by 17% growth in tablet sales and double-digit growth in...
► Artikel lesen
09.05.23ALK Abello: Three-month interim report (Q1) 2023230Revenue up 7%, full-year outlook maintained (unaudited) ALK's overall results in Q1 2023 were largely as expected, with 7% organic revenue growth in local currencies and increased operating profit...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1